Use of dorzolamide for patients with X-linked retinoschisis

Retina. 2006 Sep;26(7):741-5. doi: 10.1097/01.iae.0000237081.80600.51.


Purpose: To determine the value of a topical carbonic anhydrase inhibitor for the treatment of foveal lesions in patients with X-linked retinoschisis (XLRS).

Methods: Eight patients with XLRS and foveal cystic-appearing spaces by fundus examination and by optical coherence tomography (OCT) were treated with a topical form of carbonic anhydrase inhibitor. Changes in "foveal thickness" and "foveal zone thickness" were measured by OCT, and changes of best-corrected visual acuity were measured by Early Treatment Diabetic Retinopathy Study (ETDRS) charts.

Results: Seven of eight patients treated with 2% dorzolamide had a noticeable reduction in foveal thickness as well as cystic-appearing spaces by OCT. This reduction was found in both eyes in four of these patients and in one eye in one patient after 1 month of treatment. After an additional 1 month to 2 months of the same treatment regimen, two additional patients also had a noticeable reduction in foveal thickness as well as cystic-appearing spaces. Of these seven patients who had an improvement shown by OCT with treatment, five also had improvement of their visual acuity by >or=7 letters in at least one eye on ETDRS charts.

Conclusion: The present study shows the efficacy of topical dorzolamide for treating foveal cystic-appearing lesions in patients with XLRS.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Adult
  • Carbonic Anhydrase Inhibitors / therapeutic use*
  • Cysts / diagnosis
  • Cysts / drug therapy
  • Fovea Centralis / drug effects
  • Humans
  • Middle Aged
  • Ophthalmic Solutions / therapeutic use
  • Prospective Studies
  • Retinoschisis / diagnosis
  • Retinoschisis / drug therapy*
  • Sulfonamides / therapeutic use*
  • Thiophenes / therapeutic use*
  • Tomography, Optical Coherence
  • Visual Acuity


  • Carbonic Anhydrase Inhibitors
  • Ophthalmic Solutions
  • Sulfonamides
  • Thiophenes
  • dorzolamide